Where does Rapport Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	——	——	——	——	——
Research and development	$107.93M+13.9%	$94.79M+16.0%	$81.73M+9.0%	$74.99M+10.3%	$68M+11.6%
Selling, general and administrative	——	——	——	——	——
Other operating expenses	$142.21M+13.7%	$125.1M+13.6%	$110.11M+8.2%	$101.77M+9.3%	$93.07M+12.1%
Total operating expenses	$142.21M+13.7%	$125.1M+13.6%	$110.11M+8.2%	$101.77M+9.3%	$93.07M+12.1%
Operating income	-$122.21M+2.3%	-$125.1M-13.6%	-$110.11M-8.2%	-$101.77M-9.3%	-$93.07M-12.1%
Interest income	$14.93M+9.6%	$13.62M+9.7%	$12.41M-7.7%	$13.45M+0.6%	$13.37M+10.1%
Other income (expense), net	$14.93M+9.6%	$13.62M+9.7%	$12.41M-7.7%	$13.45M+0.6%	$13.37M+182%
Net income	-$107.28M+3.8%	-$111.48M-14.1%	-$97.7M-10.6%	-$88.31M-10.8%	-$79.7M-1.8%
Diluted earnings per share	-$2.59+9.1%	-$2.85-26.1%	-$2.26-10.2%	-$2.05+31.7%	-$3.00+77.6%
Basic earnings per share	-$2.59+9.1%	-$2.85-26.1%	-$2.26-10.2%	-$2.05+31.7%	-$3.00+77.6%
Weighted-average shares, diluted	159.5M+8.1%	147.6M+14.1%	129.4M+2.4%	126.3M+24.4%	101.5M+48.6%
Weighted-average shares, basic	159.5M+8.1%	147.6M+14.1%	129.4M+2.4%	126.3M+24.4%	101.5M+48.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$107.69M+2.5%	-$110.42M-12.7%	-$97.96M-11.1%	-$88.21M-10.8%	-$79.64M-1.0%
Share of other comprehensive (loss) income from Brookfield Asset Management ULC	-$410K-138%	$1.07M+519%	-$255K-338%	$107K+64.6%	$65K+112%
Revenue From Contract With Customer Excluding Assessed Tax	——	——	——	——	——
EBIT	-$122.21M+2.3%	-$125.1M-13.6%	-$110.11M-8.2%	-$101.77M-9.3%	-$93.07M-12.1%
EBITDA	-$121.21M+2.3%	-$124.08M-13.7%	-$109.1M-8.2%	-$100.79M-9.4%	-$92.14M-12.1%
EBITDA	-$121.21M+2.3%	-$124.08M-13.7%	-$109.1M-8.2%	-$100.79M-9.4%	-$92.14M-12.1%
EBIT	-$122.21M+2.3%	-$125.1M-13.6%	-$110.11M-8.2%	-$101.77M-9.3%	-$93.07M-12.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Rapport Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.